methane has been researched along with Gastroparesis in 2 studies
Methane: The simplest saturated hydrocarbon. It is a colorless, flammable gas, slightly soluble in water. It is one of the chief constituents of natural gas and is formed in the decomposition of organic matter. (Grant & Hackh's Chemical Dictionary, 5th ed)
methane : A one-carbon compound in which the carbon is attached by single bonds to four hydrogen atoms. It is a colourless, odourless, non-toxic but flammable gas (b.p. -161degreeC).
Gastroparesis: Chronic delayed gastric emptying. Gastroparesis may be caused by motor dysfunction or paralysis of STOMACH muscles or may be associated with other systemic diseases such as DIABETES MELLITUS.
Excerpt | Relevance | Reference |
---|---|---|
" Overall, 79 (39 %) patients with gastroparesis had evidence of SIBO by LBT: 30 (15 %) had positive H2@90min, 53 (26 %) positive DPHBT, and 6 (3 %) positive breath methane test." | 3.80 | Small intestinal bacterial overgrowth in gastroparesis. ( George, NS; Parkman, HP; Sankineni, A, 2014) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Reddymasu, SC | 1 |
McCallum, RW | 1 |
George, NS | 1 |
Sankineni, A | 1 |
Parkman, HP | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Autonomic Neuropathy, Gastrointestinal Motility, and Inflammation in HIV[NCT02850276] | Early Phase 1 | 76 participants (Actual) | Interventional | 2015-11-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"Number of participants with reduction in Small intestinal bacterial overgrowth (SIBO) assessed with breath testing after 8 weeks of treatment.~The hydrogen breath test for the detection of small intestinal bacterial overgrowth (SIBO), obtained by having participants exhale into a plastic bag. the hydrogen content of the samples is measured using a commercially available analyzer." (NCT02850276)
Timeframe: week 8
Intervention | Participants (Count of Participants) |
---|---|
Pyridostigmine | 13 |
Breath Test at week 8 as compared to baseline. Breath test results is the rise in the combined hydrogen and methane during the breath test. (NCT02850276)
Timeframe: baseline and week 8
Intervention | ppm (Median) | |
---|---|---|
Baseline | week 8 | |
Pyridostigmine | 28 | 14 |
Change in IL-6 plasma level at week 8 as compared to baseline. Plasma interleukin-6 (IL-6), an important inflammatory mediator which predicts mortality in HIV as well as multiple medical co-morbidities, presumably via inflammatory mechanisms. (NCT02850276)
Timeframe: Baseline and week 8
Intervention | mean florescence intensity (Median) | |
---|---|---|
Baseline | Week 8 | |
Pyridostigmine | 30.5 | 26.5 |
Change in sCD14 level at week 8 as compared to baseline. sCD14 is a marker of macrophage activation commonly used as an indirect measure of translocation (NCT02850276)
Timeframe: Baseline and week 8
Intervention | mean florescence intensity (Median) | |
---|---|---|
Baseline | Week 8 | |
Pyridostigmine | 2573 | 2095 |
TNFα is a pro-inflammatory cytokine which is induced by components of translocating bacteria. Change in TNFα level at week 8 compared to baseline (NCT02850276)
Timeframe: Baseline and week 8
Intervention | mean florescence intensity (Median) | |
---|---|---|
Baseline | week 8 | |
Pyridostigmine | 134.0 | 117.5 |
Percent retention of gastric contents on gastric emptying study. GI dysmotility calculated from gastric emptying scintigraphy - measurement of the percent retention of gastric contents at 4 hours. (NCT02850276)
Timeframe: Baseline and week 8
Intervention | percent retention of gastric contents (Mean) | |
---|---|---|
Baseline | week 8 | |
Pyridostigmine | 3 | 2 |
Medical Outcomes Study (MOS-HIV) quality of life questionnaire. It is a 35 item questionnaire covering 11 dimensions of health including physical functioning, role functioning, pain, social functioning, emotional well-being, energy/fatigue, cognitive functioning, general health, health distress, overall QOL, and health transition. The total scale ranges from 0-100 with a higher score representing better functioning and well-being. (NCT02850276)
Timeframe: Baseline and week 8
Intervention | score on a scale (Mean) | |
---|---|---|
Baseline | Week 8 | |
Pyridostigmine | 66.1 | 65 |
The gastrointestinal domain domain score of the COMPASS contains 12 items which reflect gastrointestinal symptoms of autonomic function. It is scored on a total scale of 0-28, with higher numbers reflecting worse symptoms. (NCT02850276)
Timeframe: Baseline and week 8
Intervention | score on a scale (Mean) | |
---|---|---|
Baseline | Week 8 | |
Pyridostigmine | 8 | 8.6 |
2 other studies available for methane and Gastroparesis
Article | Year |
---|---|
Small intestinal bacterial overgrowth in gastroparesis: are there any predictors?
Topics: Abdominal Pain; Adult; Breath Tests; Cohort Studies; Female; Gastric Emptying; Gastroparesis; Glucos | 2010 |
Small intestinal bacterial overgrowth in gastroparesis.
Topics: Adult; Biomarkers; Breath Tests; Female; Gastroparesis; Humans; Hydrogen; Intestine, Small; Lactulos | 2014 |